Antibiotic therapy for Klebsiella pneumoniae bacteremia: Implications of production of extended-spectrum β-lactamases

Clinical Infectious Diseases

Volumn 39, Issue 1, 2004, Pages 31-37

  Paterson, David L ^a,b   Ko, Wen Chien ^c   Von Gottberg, Anne ^d   Mohapatra, Sunita ^e   Casellas, Jose Maria ^f   Goossens, Herman ^g   Mulazimoglu, Lutfiye ^h   Trenholme, Gordon ^e   Klugman, Keith P ^d   Bonomo, Robert A ⁱ   Rice, Louis B ⁱ   Wagener, Marilyn M ^a   McCormack, Joseph G ^b   Yu, Victor L ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d South African Institute of Medical Research   (South Africa)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f Sanatorio San Lucas   (Argentina)

^g ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^h MARMARA UNIVERSITY   (Turkey)

ⁱ LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; BETA LACTAM; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CARBAPENEM; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BLOOD CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; ENTEROBACTER INFECTION; ENZYME SYNTHESIS; FEMALE; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MALE; MONOTHERAPY; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; FEMALE; HUMANS; IMIPENEM; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MULTIVARIATE ANALYSIS;

EID: 3042706689     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/420816     Document Type: Article

References (32)

1. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat [review]. Clin Microbiol Rev 2001; 14:933-51.
2. Paterson DL, Hujer KM, Hujer AM, et al. Extended-spectrum β-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type β-lactamases. Antimicrob Agents Chemother 2003; 47: 3554-60.
3. National Nosocomial Infections Surveillance. National Nosocomial Infections Surveillance (NNIS) system report: data summary from January 1992 to June 2002, issued August 2002. Am J Infect Control 2002; 30:458-75.
4. Bell JM, Turnidge JD, Gales AC, Pfaller MA, Jones RN. Prevalence of extended spectrum β-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998-99). Diagn Microbiol Infect Dis 2002; 42:193-8.
5. Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 2001; 32(Suppl 2): S94-103.
6. Babini GS, Livermore DM. Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998. J Antimicrob Chemother 2000; 45:183-9.
7. Goossens H. MYSTIC program: summary of European data from 1997 to 2000. Diagn Microbiol Infect Dis 2001; 41:183-9.
8. Paterson DL, Mulazimoglu L, Casellas JM, et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000; 30:473-8.
9. Ko WC, Paterson DL, Sagnimeni AJ, et al. Community-acquired Klebsiella pneumoniae bacteremia: global differences in clinical patterns. Emerg Infect Dis 2002; 8:160-6.
10. Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system: risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991; 100:1619-36.
11. Korvick JA, Bryan CS, Farber B, et al. Prospective observational study of Klebsiella bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapy. Antimicrob Agents Chemother 1992; 36:2639-44.
12. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115:585-90.
13. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87:540-6.
14. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16: 128-40.
15. NCCLS. Performance standards for antimicrobial susceptibility testing. 11th Informational supplement. Wayne, PA: NCCLS, 1999. NCCLS document M100-S10.
16. Baig H, Reid Miller M. Prophet statistics: a user's guide to statistical analysis on the Prophet system. Bethesda, MD: National Institutes of Health, 1980.
17. Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001; 45:3548-54.
18. Rice LB, Yao JD, Klimm K, Eliopoulos GM, Moellering RC Jr. Efficacy of different β-lactams against an extended-spectrum β-lactamase-producing Klebsiella pneumoniae strain in the rat intra-abdominal abscess model. Antimicrob Agents Chemother 1991; 35:1243-4.
19. Thauvin-Eliopoulos C, Tripodi MF, Moellering RC Jr, Eliopoulos GM. Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum β-lactamase-producing strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 1997; 41:1053-7.
20. Fantin B, Pangon B, Potel G, et al. Activity of sulbactam in combination with ceftriaxone in vitro and in experimental endocarditis caused by Escherichia coli producing SHV-2-like β-lactamase. Antimicrob Agents Chemother 1990; 34:581-6.
21. Szabo D, Mathe A, Filetoth Z, Anderlik P, Rokusz L, Rozgonyi F. In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum β-lactamase-producing Klebsiella pneumoniae strain. Antimicrob Agents Chemother 2001; 45:1287-91.
22. Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, Fishman NO. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 2001; 33:1288-94.
23. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993; 119:353-8.
24. Bingen EH, Desjardins P, Arlet G, et al. Molecular epidemiology of plasmid spread among extended broad-spectrum β-lactamase-producing Klebsiella pneumoniae isolates in a pediatric hospital. J Clin Microbiol 1993; 31:179-84.
25. Burgess DS, Hall RG 2nd, Lewis JS 2nd, Jorgensen JH, Patterson JE. Clinical and microbiologic analysis of a hospital's extended-spectrum β-lactamase-producing isolates over a 2-year period. Pharmacotherapy 2003; 23:1232-7.
26. de Champs C, Guelon D, Joyon D, Sirot D, Chanal M, Sirot J. Treatment of a meningitis due to an Enterobacter aerogenes producing a derepressed cephalosporinase and a Klebsiella pneumoniae producing an extended-spectrum β-lactamase. Infection 1991; 19:181-3.
27. Emery CL, Weymouth LA. Detection and clinical significance of extended-spectrum β-lactamases in a tertiary-care medical center. J Clin Microbiol 1997; 35:2061-7.
28. French GL, Shannon KP, Simmons N. Hospital outbreak of Klebsiella pneumoniae resistant to broad-spectrum cephalosporins and β-lactam-β- lactamase inhibitor combinations by hyperproduction of SHV-5 β-lactamase. J Clin Microbiol 1996; 34:358-63.
29. Pena C, Pujol M, Ardanuy C, et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum β-lactamases. Antimicrob Agents Chemother 1998; 42:53-8.
30. Royle J, Halasz S, Eagles G, et al. Outbreak of extended spectrum β lactamase producing Klebsiella pneumoniae in a neonatal unit. Arch Dis Child Fetal Neonatal Ed 1999; 80-F64-8.
31. Siu LK, Lu PL, Hsueh PR, et al. Bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a pédiatrie oncology ward: clinical features and identification of different plasmids carrying both SHV-5 and TEM-1 genes. J Clin Microbiol 1999; 37:4020-7.
32. Segal-Maurer S, Mariano N, Qavi A, Urban C, Rahal JJ Jr. Successful treatment of ceftazidime-resistant Klebsiella pneumoniae ventriculitis with intravenous meropenem and intraventricular polymyxin B: case report and review. Clin Infect Dis 1999; 28:1134-8.